Durata Therapeutics, Inc. has announced that DALVANCE™  (dalbavancin) for injection is now available for use to treat adult patients with acute bacterial skin and skin structure infections. DALVANCE was approved by the U.S. Food and Drug Administration on May 23, 2014 and was the first drug approved as a Qualified Infectious Disease Product.

“DALVANCE’s unique dosing regimen offers a new approach to treatment of serious skin infections by allowing patients, healthcare professionals and hospitals to move beyond the standard daily or twice-daily IV antibiotic infusions,” said Paul R. Edick, Durata’s CEO.